Pfizer's Comeback Accelerates

Pfizer reported robust Q2 2025 results, with revenue growing 10% year-over-year to $14.7 billion, primarily driven by the Abrysvo RSV vaccine and acquired Seagen oncology assets, while an 8% reduction in adjusted operating expenses boosted adjusted EPS by 31%. Management projects over $20 billion in risk-adjusted revenue from new launches by 2030, largely offsetting an anticipated $17-$20 billion in patent expirations, supported by a significant ~$11 billion R&D investment in 28 Phase 3 programs. This strategic focus aims to mitigate post-COVID revenue declines and the patent cliff, with a projected 2025-26 EPS of $3.00-$3.15 implying a potential share valuation of $31-$45.

Analysis

Pfizer's Q2 2025 results demonstrate a significant operational turnaround, with revenue growing 10% year-over-year to $14.7 billion. This growth is critically driven by new products, namely the Abrysvo RSV vaccine and the oncology assets from the Seagen acquisition, signaling a successful strategic pivot away from declining COVID-related revenues. Concurrently, the company has enhanced profitability through effective cost management, evidenced by an 8% reduction in adjusted operating expenses that fueled a 31% increase in adjusted earnings per share. Management has directly addressed concerns over the upcoming patent cliff by projecting over $20 billion in risk-adjusted revenue from new launches by 2030, which is sized to fully offset the $17–$20 billion impact of patent expirations. This forward-looking guidance is supported by a substantial R&D investment of approximately $11 billion in 2025, funding a robust pipeline of 28 Phase 3 programs. Based on a 2025-26 EPS forecast of $3.00–$3.15, the provided analysis implies a valuation range of $31–$45 per share, complemented by an attractive dividend yield.

Key Decisions for Investors

• Given the strong revenue growth from non-COVID products and significant margin improvement, investors should re-evaluate Pfizer as a growth story rather than a company in post-pandemic decline.
• Monitor the progress of the 28 Phase 3 programs and the revenue trajectory of new launches, as successful execution is critical to validating management's forecast of offsetting the $17-$20 billion patent cliff by 2030.
• With a valuation framework suggesting a share price of $31-$45 and an attractive dividend, the stock warrants consideration for both value and income-oriented portfolios, contingent on continued execution on stated cost-control and pipeline goals.